Cytek Biosciences, Inc. (CTKB) Institutional Ownership

Ownership Summary

Cytek Biosciences, Inc. (NASDAQ:CTKB) appears in 151 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 64.3% of Cytek Biosciences's outstanding shares in December 2025, up from 63.3% in September 2025.
• Their total shares held in CTKB increased 3.57% quarter over quarter, and separately, investors owning Cytek Biosciences decreased 0.66% from a year ago.
• Among the 151 funds, 72 bought more Cytek Biosciences shares, 60 sold down, and 19 held their ground.
• The aggregate institutional position in Cytek Biosciences amounted to 81.97Mn shares as of December 2025, up by 2.82Mn shares quarter on quarter, and up 794.16K shares year over year.
• BlackRock, Inc. leads ownership in CTKB with 17.17Mn shares as of December 31, 2025, equal to 13.46% of outstanding shares.
• Top purchasers of CTKB stock for the quarter ending December 2025 included Boston Partners (4.97Mn), MILLENNIUM MANAGEMENT LLC (1.33Mn), Russell Investments Group, Ltd. (841.61K), BlackRock, Inc. (625.34K), VANGUARD GROUP INC (541.97K).
• The biggest sellers of Cytek Biosciences for the quarter ending December 2025 included BROWN CAPITAL MANAGEMENT LLC (2.89Mn), WELLINGTON MANAGEMENT GROUP LLP (1.78Mn), DIMENSIONAL FUND ADVISORS LP (570.9K), JACOBS LEVY EQUITY MANAGEMENT, INC (560.26K), Jpmorgan Chase & Co (388.59K).
• According to Business Quant data, leading holders of CTKB for December 2025 are BlackRock, Inc. (17.17Mn), VANGUARD GROUP INC (7.48Mn), Topline Capital Management, LLC (7.44Mn), HHLR ADVISORS, LTD. (6.66Mn), Boston Partners (5.01Mn), MILLENNIUM MANAGEMENT LLC (4.75Mn), State Street Corp (4.15Mn), GEODE CAPITAL MANAGEMENT, LLC (2.79Mn), DIMENSIONAL FUND ADVISORS LP (2.65Mn), BROWN CAPITAL MANAGEMENT LLC (2.07Mn).